세포 및 유전자 치료 위탁개발 제조(CDMO) 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The Cell And Gene Therapy CDMO Market size is expected to reach USD 34.04 Billion in 2034 from USD 7.47 Billion (2025) growing at a CAGR of 18.36% during 2026-2034.

The global cell and gene therapy CDMO market is growing rapidly as pharmaceutical and biotechnology companies increasingly outsource complex manufacturing processes. Rising investments in advanced therapies for cancer, rare diseases, and genetic disorders are fueling demand for specialized contract development and manufacturing organizations (CDMOs). The complexity of cell and gene therapies requires advanced facilities and regulatory expertise, encouraging outsourcing partnerships.

Key drivers include expanding clinical pipelines and the growing number of regulatory approvals for gene-modified therapies. High manufacturing costs and the need for scalability further boost reliance on experienced CDMOs. Additionally, strategic collaborations between biotech firms and CDMOs are accelerating product development timelines and improving supply chain efficiency.

In the future, the market is expected to expand with improvements in viral vector production, automation technologies, and cold chain logistics. Increasing global clinical trial activity and supportive regulatory frameworks will continue to create strong opportunities for CDMOs.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Phase

• Pre-Clinical
• Clinical

By Product Type

• Gene Therapy (Ex-Vivo, In-Vivo)
• Gene-Modified Cell Therapy (Car T-Cell Therapies, Car-Nk Cell Therapy, Tcr-T Cell Therapy, Other)
• Cell Therapy

By Indication

• Oncology
• Infectious Diseases
• Neurological Disorders
• Rare Diseases
• Others

COMPANIES PROFILED

• Lonza, Catalent Inc, Cytiva, Samsung Biologics, Thermo Fisher Scientific Inc, WuXi AppTec, AGC Biologics, OmniaBio, Charles River Laboratories
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL CELL AND GENE THERAPY CDMO MARKET: BY PHASE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Phase
• 4.2. Pre-Clinical Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Clinical Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL CELL AND GENE THERAPY CDMO MARKET: BY PRODUCT TYPE 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Product Type
• 5.2. Gene Therapy (Ex-Vivo, In-Vivo) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Gene-Modified Cell Therapy (Car T-Cell Therapies, Car-Nk Cell Therapy, Tcr-T Cell Therapy, Other) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Cell Therapy Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL CELL AND GENE THERAPY CDMO MARKET: BY INDICATION 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Indication
• 6.2. Oncology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Infectious Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Neurological Disorders Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.5. Rare Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.6. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL CELL AND GENE THERAPY CDMO MARKET: BY REGION 2022-2034(USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Phase
  • 7.2.2 By Product Type
  • 7.2.3 By Indication
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Phase
  • 7.3.2 By Product Type
  • 7.3.3 By Indication
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Phase
  • 7.4.2 By Product Type
  • 7.4.3 By Indication
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Phase
  • 7.5.2 By Product Type
  • 7.5.3 By Indication
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 South East Asia
  • 7.5.9 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Phase
  • 7.6.2 By Product Type
  • 7.6.3 By Indication
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL CELL AND GENE THERAPY CDMO INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 Lonza
  • 9.2.2 Catalent Inc
  • 9.2.3 Cytiva
  • 9.2.4 Samsung Biologics
  • 9.2.5 Thermo Fisher Scientific Inc
  • 9.2.6 WuXi AppTec
  • 9.2.7 AGC Biologics
  • 9.2.8 OmniaBio
  • 9.2.9 Charles River Laboratories